Single-cell RNA-sequencing combined with bulk RNA-sequencing analysis of peripheral blood reveals the characteristics and key immune cell genes of ulcerative colitis

BACKGROUND Ulcerative colitis (UC) is a complicated disease caused by the interaction between genetic and environmental factors that affects mucosal homeostasis and triggers an inappropriate immune response. Single-cell RNA sequencing (scRNA-seq) can be used to rapidly obtain the precise gene expression patterns of thousands of cells in the intestine, analyze the characteristics of cells with the same phenotype, and provide new insights into the growth and development of intestinal organs, the clonal evolution of cells, and immune cell changes. These findings can provide new ideas for the diagnosis and treatment of intestinal diseases. AIM To identify clinical phenotypes and biomarkers that can predict the response of UC patients to specific therapeutic drugs and thus aid the diagnosis and treatment of UC. METHODS Using the Gene Expression Omnibus (GEO) database, we analyzed peripheral blood cell subtypes of patients with UC by scRNA-seq combined with bulk RNA sequencing (RNA-seq) to reveal the core genes of UC. We then combined weighted gene correlation network analysis (WGCNA) and least absolute shrinkage and selection operator (LASSO) analysis to reveal diagnostic markers of UC. RESULTS After processing the scRNA-seq data, we obtained data from approximately 24340 cells and identified 17 cell types. Through intercellular communication analysis, we selected monocyte marker genes as the candidate gene set for the prediction model. Construction of a WGCNA coexpression network identified RhoB, cathepsin D (CTSD) and zyxin (ZYX) as core genes. Immune infiltration analysis showed that these three core genes were strongly correlated with immune cells. Functional enrichment analysis showed that the differentially expressed genes were closely related to immune and inflammatory responses, which are associated with many challenges in the diagnosis and treatment of UC. CONCLUSION Through scRNA-seq analysis, LASSO diagnostic model building and WGCNA, we identified RhoB, CTSD and ZYX as core genes of UC that are closely related to monocyte infiltration that may serve as diagnostic markers and molecular targets for UC therapeutic intervention.

[1]  C. Lamb,et al.  The future of precision medicine to predict outcomes and control tissue remodeling in inflammatory bowel disease. , 2021, Gastroenterology.

[2]  A. Hart,et al.  How should pain, fatigue and emotional wellness be incorporated into treatment goals for optimal management of IBD? , 2021, Gastroenterology.

[3]  C. Le Berre,et al.  Evolving short- and long-term goals of management of IBD: getting it right, making it last , 2022, Gastroenterology.

[4]  M. Parkes,et al.  How do we predict a patient's disease course and whether they will respond to specific treatments? , 2021, Gastroenterology.

[5]  S. Danese,et al.  Breaking through the therapeutic ceiling: what will it take? , 2021, Gastroenterology.

[6]  Xinying Wang,et al.  Treatment Decision-making in Chinese Inflammatory Bowel Disease Patients. , 2021, Inflammatory bowel diseases.

[7]  A. Zaraisky,et al.  Cytoskeletal protein Zyxin in embryonic development: from controlling cell movements and pluripotency to regulating embryonic patterning , 2021, The FEBS journal.

[8]  L. Peyrin-Biroulet,et al.  Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. , 2021, The lancet. Gastroenterology & hepatology.

[9]  Y. Hiasa,et al.  Association Between Peripheral Blood Monocyte Count and Mucosal Healing in Japanese Patients With Ulcerative Colitis , 2021, Clinical and translational gastroenterology.

[10]  Zhi-Peng Tang,et al.  Regulation of Endoplasmic Reticulum Stress-Autophagy: A Potential Therapeutic Target for Ulcerative Colitis , 2021, Frontiers in Pharmacology.

[11]  A. Gryglewski,et al.  Changes in γδT Cells in Peripheral Blood of Patients with Ulcerative Colitis Exacerbations , 2021, Archivum immunologiae et therapiae experimentalis.

[12]  B. Cillero-Pastor,et al.  Inhibition of Extracellular Cathepsin D Reduces Hepatic Lipid Accumulation and Leads to Mild Changes in Inflammationin NASH Mice , 2021, Frontiers in Immunology.

[13]  P. Hegyi,et al.  Granulocyte and monocyte apheresis as an adjunctive therapy to induce and maintain clinical remission in ulcerative colitis: a systematic review and meta-analysis , 2021, BMJ Open.

[14]  Qijin Yin,et al.  Identification of monocyte-associated genes as predictive biomarkers of heart failure after acute myocardial infarction , 2021, BMC Medical Genomics.

[15]  Cheng-Jian Xu,et al.  Identification of Novel Population-Specific Cell Subsets in Chinese Ulcerative Colitis Patients Using Single-Cell RNA Sequencing , 2021, Cellular and molecular gastroenterology and hepatology.

[16]  Judy H. Cho,et al.  Inflamed ulcerative colitis regions associated to MRGPRX2-mediated mast cell degranulation and cell activation modules, defining a new therapeutic target. , 2021, Gastroenterology.

[17]  E. Mukamel,et al.  Single-Cell Sequencing of Brain Cell Transcriptomes and Epigenomes , 2021, Neuron.

[18]  P. Loke,et al.  Single Cell Transcriptional Survey of Ileal-Anal Pouch Immune Cells from Ulcerative Colitis Patients. , 2020, Gastroenterology.

[19]  D. Tian,et al.  Comprehensive analysis of key biomarkers, immune infiltration and potential therapeutic agents for ulcerative colitis. , 2020, Life sciences.

[20]  M. Sarfati,et al.  Single-Cell Protein and RNA Expression Analysis of Mononuclear Phagocytes in Intestinal Mucosa and Mesenteric Lymph Nodes of Ulcerative Colitis and Crohn’s Disease Patients , 2020, Cells.

[21]  F. Jamali,et al.  Single dose pharmacokinetics and bioavailability of glucosamine in the rat. , 2002, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[22]  F. Kondo,et al.  Adsorptive Granulocyte and Monocyte Apheresis Is Effective in Ulcerative Colitis Patients Both with and without Concomitant Prednisolone , 2020, Inflammatory Intestinal Diseases.

[23]  L. Peyrin-Biroulet,et al.  Evolving therapeutic goals in ulcerative colitis: towards disease clearance , 2019, Nature Reviews Gastroenterology & Hepatology.

[24]  Aviv Regev,et al.  Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis , 2019, Cell.

[25]  H. Ebada,et al.  Neutrophil/lymphocyte ratio and lymphocyte/monocyte ratio in ulcerative colitis as non-invasive biomarkers of disease activity and severity , 2019, Autoimmunity Highlights.

[26]  Ashwin N. Ananthakrishnan,et al.  ACG Clinical Guideline: Ulcerative Colitis in Adults , 2019, The American journal of gastroenterology.

[27]  G. Genovese,et al.  Role of Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease , 2018, Journal of Crohn's & colitis.

[28]  Y-X Wang,et al.  Zyxin: a mechanotransductor to regulate gene expression. , 2019, European review for medical and pharmacological sciences.

[29]  A. Cambi,et al.  Super-Resolution Correlative Light and Electron Microscopy (SR-CLEM) Reveals Novel Ultrastructural Insights Into Dendritic Cell Podosomes , 2018, Front. Immunol..

[30]  S. Lele,et al.  Zyxin promotes colon cancer tumorigenesis in a mitotic phosphorylation-dependent manner and through CDK8-mediated YAP activation , 2018, Proceedings of the National Academy of Sciences.

[31]  X. Suárez-Calvet,et al.  Inverse Association Between Circulating Monocyte-Platelet Complexes and Inflammation in Ulcerative Colitis Patients. , 2018, Inflammatory bowel diseases.

[32]  P. Lepage,et al.  TREM-1 Inhibition Restores Impaired Autophagy Activity and Reduces Colitis in Mice , 2018, Journal of Crohn's & colitis.

[33]  V. V. van Hinsbergh,et al.  RhoA, RhoB and RhoC differentially regulate endothelial barrier function , 2017, Small GTPases.

[34]  Shuyuan Liu,et al.  RhoB induces the production of proinflammatory cytokines in TLR‐triggered macrophages , 2017, Molecular immunology.

[35]  C. Langner,et al.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. , 2017, Journal of Crohn's & colitis.

[36]  S. Brierley,et al.  Acute colitis chronically alters immune infiltration mechanisms and sensory neuro-immune interactions , 2017, Brain, Behavior, and Immunity.

[37]  G. Thomas,et al.  Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis , 2016, Oncoimmunology.

[38]  M. Zimmerman,et al.  Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity , 2015, Inflammatory bowel diseases.

[39]  A. Hart,et al.  Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview , 2015, The American Journal of Gastroenterology.

[40]  Bo Li,et al.  Decreased expression of cathepsin D in monocytes is related to the defective degradation of amyloid-β in Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[41]  Yongzhi Yang,et al.  Overexpression of miR-21 in patients with ulcerative colitis impairs intestinal epithelial barrier function through targeting the Rho GTPase RhoB. , 2013, Biochemical and biophysical research communications.

[42]  G. Rogler,et al.  Sphingomyelin induces cathepsin D-mediated apoptosis in intestinal epithelial cells and increases inflammation in DSS colitis , 2010, Gut.

[43]  G. Prendergast,et al.  Loss of RhoB Expression Enhances the Myelodysplastic Phenotype of Mammalian Diaphanous-Related Formin mDia1 Knockout Mice , 2009, PloS one.

[44]  J. Schwab,et al.  Lesional expression of RhoA and RhoB following traumatic brain injury in humans. , 2004, Journal of neurotrauma.

[45]  G. Rogler,et al.  Cathepsin D is up‐regulated in inflammatory bowel disease macrophages , 2004, Clinical and experimental immunology.